ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Chong Kun Dang Pharmaceutical and Celltrion side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Chong Kun Dang PharmaceuticalCelltrion
studies on the registry29984
open to participants now144
phase 3 studies under way25
reach primary completion within a year46
programswith a study of their own in two years1815

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseChong Kun Dang PharmaceuticalCelltrion
Phase 1

Chong Kun Dang Pharmaceutical: 13 of its 18 programs at phase 1

  1. CKD-383phase 1
  2. CKD-215phase 1
  3. CKD-512phase 1
  4. CKD-704phase 1
  5. CKD-706phase 1

and 8 more — sign in to see them all

72%

Celltrion: 6 of its 15 programs at phase 1

  1. ixekizumabphase 1
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. CT-P52phase 1
  5. CTL02phase 1

and 1 more — sign in to see them all

40%
Phase 2

Chong Kun Dang Pharmaceutical: 1 of its 18 programs at phase 2

  1. Anti-c-Met/MMAE Antibody-drug Conjugate CKD-703phase 2
6%
00%
Phase 3

Chong Kun Dang Pharmaceutical: 2 of its 18 programs at phase 3

  1. CKD-843phase 3
  2. lobeglitazonephase 3
11%

Celltrion: 9 of its 15 programs at phase 3

  1. CT-P55phase 3
  2. CT-P51phase 3
  3. daratumumabphase 3
  4. empagliflozinphase 3
  5. CT-P43phase 3

and 4 more — sign in to see them all

60%
Approved, new studies

Chong Kun Dang Pharmaceutical: 2 of its 18 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Everolimusapproved, new study
11%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Chong Kun Dang Pharmaceutical5 readouts · 2 phase 3····

Chong Kun Dang Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion

  1. CKD-512phase 1 · Mar 0 · NCT07215637
··

Chong Kun Dang Pharmaceutical, Jun ’27: 2 programs whose next study reaches primary completion

  1. CKD-215phase 1 · Jun 0 · NCT07532148
  2. D215phase 1 · Jun 0 · NCT07532148
·

Chong Kun Dang Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinapproved, new study · Aug 0 · NCT07365358

Chong Kun Dang Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CKD-843phase 3 · Sep 30 · NCT06916793
·
Celltrion3 readouts · 3 phase 3·

Celltrion, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinphase 3 · Dec 0 · NCT07093476
·

Celltrion, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CT-P51phase 3 · Feb 0 · NCT06939595

Celltrion, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. daratumumabphase 3 · Mar 8 · NCT06952478
·······
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Chong Kun Dang Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Celltrion

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionChong Kun Dang PharmaceuticalCelltrion
Diabetes Mellitus, Type 2both · compare here

Chong Kun Dang Pharmaceutical in Diabetes Mellitus, Type 2: 4 programs

  1. lobeglitazonephase 3
  2. CKD-383phase 1
  3. CKD-378phase 1
  4. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Celltrion in Diabetes Mellitus, Type 2: 4 programs

  1. empagliflozinphase 3
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. L03TD1phase 1

Their studies: Celltrion’s studies of Diabetes Mellitus, Type 2 in search

Hypertensionboth · compare here

Chong Kun Dang Pharmaceutical in Hypertension: 1 program

  1. CKD-339phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Hypertension in search

Celltrion in Hypertension: 3 programs

  1. rosuvastatinphase 3
  2. Amlodipinephase 3
  3. Ezetimibephase 3

Their studies: Celltrion’s studies of Hypertension in search

Psoriasisboth · compare here

Chong Kun Dang Pharmaceutical in Psoriasis: 1 program

  1. CKD-704phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Psoriasis in search

Celltrion in Psoriasis: 3 programs

  1. CT-P55phase 3
  2. CT-P43phase 3
  3. ixekizumabphase 1

Their studies: Celltrion’s studies of Psoriasis in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Chong Kun Dang Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Anti-c-Met/MMAE Antibody-drug Conjugate CKD-703phase 2
  2. Everolimusapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Celltrion in Carcinoma, Non-Small-Cell Lung: 1 program

  1. CT-P51phase 3

Their studies: Celltrion’s studies of Carcinoma, Non-Small-Cell Lung in search

Dyslipidemiasboth · compare here

Chong Kun Dang Pharmaceutical in Dyslipidemias: 2 programs

  1. D352phase 1
  2. D794phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Dyslipidemias in search

Celltrion in Dyslipidemias: 1 program

  1. rosuvastatinphase 3

Their studies: Celltrion’s studies of Dyslipidemias in search

Diabetes Mellitus, Lipoatrophicboth · compare here

Chong Kun Dang Pharmaceutical in Diabetes Mellitus, Lipoatrophic: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Diabetes Mellitus, Lipoatrophic in search

Celltrion in Diabetes Mellitus, Lipoatrophic: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Diabetes Mellitus, Lipoatrophic in search

Diabetes Mellitus, Type 1both · compare here

Chong Kun Dang Pharmaceutical in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Diabetes Mellitus, Type 1 in search

Celltrion in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Diabetes Mellitus, Type 1 in search

Heart Failureboth · compare here

Chong Kun Dang Pharmaceutical in Heart Failure: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Heart Failure in search

Celltrion in Heart Failure: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Heart Failure in search

Renal Insufficiency, Chronicboth · compare here

Chong Kun Dang Pharmaceutical in Renal Insufficiency, Chronic: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Renal Insufficiency, Chronic in search

Celltrion in Renal Insufficiency, Chronic: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Renal Insufficiency, Chronic in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetChong Kun Dang PharmaceuticalCelltrion
SLC5A2empagliflozinruleempagliflozinrule
A target, or a pathogen for a vaccine, known for: Chong Kun Dang Pharmaceutical 3 of 18 · Celltrion 6 of 15 programs (9 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.